Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5801–5850 of 18644
appointed Steven J. Moskowitz to serve as the President and CEO and as a member of the Board, effective April 11, 2024
On April 10 2024, Ms. Shuhua Liu resigned as CEO of Summit Networks Inc.
Mr. Stephen Kok Koon Tan ("Mr. Tan") as the new CEO as well as a Director
The Board of Directors (the “Board”) of Brightcove Inc., a Delaware corporation (the “Company”) elected John Wagner as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Treasurer of the Company, effective on April 10, 2024
Mr. Noreck will resign from such roles and transition into the role of a consultant as of the Effective Date.
Dr. Urban Forssell, mutually agreed that Dr. Forssell will step down as President and CEO effective immediately.
the Board appointed the Company’s Chief Financial Officer, Fredrik Nihlén, as the Company’s Interim President and CEO effective immediately.
Scott Hill, the Company's existing Chief Executive Officer, will remain as an employee of the Company on an interim basis from the Start Date until May 11, 2024, as an advisor to Mr. Friedrichsen and to help provide for an orderly transition.
On April 9, 2024 the board of directors (the "Board") of CS Disco, Inc. (the "Company") appointed Eric Friedrichsen as the Company's President, Chief Executive Officer and principal executive officer, effective April 29, 2024
On April 9, 2024, the Board of Directors of Forza X1, Inc. (the “Company”) appointed Michael P. Dickerson to serve as Interim Chief Financial & Administrative Officer of the Company.
On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
the appointment of Thomas C. Gentile III as Chief Executive Officer and President of the Company, in each case, effective May 1, 2024.
Ankur Dhingra has been appointed Chief Financial Officer of the Company, effective April 15, 2024
Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.
On April 8, 2024, Angi Inc. (the “Registrant” or “Angi”) announced that Jeffrey W. Kip, President of Angi, was appointed to succeed Joseph Levin as Chief Executive Officer of Angi and will be appointed as a member of the Angi board of directors, effective immediately.
As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.
On April 8, 2024, the board of directors (the “Board”) of Serve Robotics Inc. (the “Company”) appointed Brian Read as the Company’s Chief Financial Officer, effective on or around April 29, 2024
On April 8, 2024, the Company accepted the resignation of April Pannell, the Company’s Chief Financial Officer, effective as of the Effective Date, upon the commencement of Mr. Read’s employment.
Effective on April 9, 2024, Mr. Kuch will step down from his role as Chief Financial Officer of the Company.
on April 9, 2024 (the “Start Date”), Mr. Bart Cornelissen, age 46, was appointed as Senior Vice President and Chief Financial Officer of the Company for an indefinite term.
On April 5, 2024, the Board of Directors (the “Board”) of Wrap Technologies, Inc. (the “Company”) appointed Scot Cohen (“Mr. Cohen”), who serves as the Company’s Executive Chairman and Chief Executive Officer, and as its Principal Executive Officer, to the position of Interim Principal Financial Officer and Principal Accounting Officer, effective immediately.
the parties agreed that Mr. Vogel’s final date of employment would be the date of the closing of the Merger and that his termination of employment on the date of the closing of the Merger would constitute a termination by Mr. Vogel for Good Reason
Nimrod Ben-Natan, currently Senior Vice President and General Manager of the Company’s Broadband business, has been appointed as CEO of the Company by the Company’s board of directors (the “Board”), effective as of the Effective Date.
Patrick Harshman, the Company’s President and Chief Executive Officer (“CEO”), will retire as CEO, effective as of June 11, 2024
On April 8, 2024, the Company announced the Board’s current intention to appoint David Rawden of AlixPartners, a business advisory firm currently providing a variety of consulting services to the Company, to serve as the Company’s Interim Chief Financial Officer upon Mr. Tsoumas’ retirement.
On April 8, 2024, Methode Electronics, Inc. (the “Company”) announced that Ronald L.G. Tsoumas, its Chief Financial Officer, plans to retire effective July 12, 2024
Ms. Madhu Ranganathan as President, CFO & Corporate Development
On April 6, 2024, the Board of Directors of the Company approved the appointment of Daniel Otto as its Chief Financial Officer, effective immediately.
On April 6, 2024, Hugh Kinsman, the Company’s Chief Financial Officer, provided notice that he is resigning from such position effective June 1, 2024.
the Company’s Chief Executive Officer, Denton Peng, will assume the duties as principal financial officer and principal accounting officer of the Company.
the Company accepted the resignation of Mr. J. Mark Hastings as Chief Financial Officer of the Company effective as of April 10, 2024.
On April 5, 2024, Gain Therapeutics, Inc. (the “Company”) appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024
all of the Company's officers immediately prior to the Effective Time resigned as officers of the Company.
On April 8, 2024, Blackstone Private Equity Strategies Associates, L.P., the general partner of Blackstone Private Equity Strategies Fund L.P. (the “Fund”), appointed Viral Patel as the Chief Executive Officer of the Fund, effective immediately.
On April 2, 2024, James Bradley resigned as Chief Financial Officer of New Providence Acquisition Corp. II (the “ Company ”), effective immediately.
Gary P. Smith, the Company’s Chief Executive Officer and director, will serve as the Company’s interim Chief Financial Officer until such time that the Board has appointed a new Chief Financial Officer.
Effective April 12, 2024, Sachin Gupta, the Financial Controller of the Company, will serve as the interim as the principal financial and accounting officer of the Company.
On April 4, 2024, Zoomcar Holdings, Inc. (the “ Company ”) and Geiv Dubash, the Chief Financial Officer of the Company, agreed to a mutual separation of employment, effective April 12, 2024.
On April 2, 2024, Patriot National Bancorp, Inc. (the “Company”) received a notice of retirement from Joseph Perillo, Chief Financial Officer and Executive Vice President of the Company and its subsidiary Patriot Bank, N.A. (the “Bank”), announcing his retirement and intention to continue on his current position to assist the Company during the transition period to appoint a new Chief Financial Officer, with a targeted end day of July 31, 2024.
the Company’s Board of Directors (the “Board”) had unanimously approved Marla Beck to be the Company’s President and Chief Executive Officer.
David Naemura will continue as the Company’s Chief Financial Officer and Mr. Moylan will serve as the Company’s Principle Accounting Officer, replacing Mr. Naemura in that role.
the Company has appointed Ewout L. Steenbergen as its Executive Vice President and Chief Financial Officer effective as of March 15, 2024.
Andrew Kucharchuk, age 43, succeeded Mr. Lazarus as the Company’s Chief Financial Officer, effective April 1, 2024.
On April 1, 2024, Roger Lazarus, the Chief Financial Officer of Chain Bridge I (the “Company”), notified the board of directors of the Company (the “Board”) of his resignation, effective immediately.
On April 5, 2024, the Board of Directors of the Company appointed Albert N. Marchio II as Interim Chief Financial Officer and designated him to serve as the principal financial officer and principal accounting officer of the Company effective upon Mr. Stover’s resignation (the “Transition Date”).
On April 1, 2024, Timothy Stover, Vice President, Corporate Controller and the principal financial officer and principal accounting officer of NexImmune, Inc. (the “Company”), notified the Company of his intention to resign from all positions he holds at the Company, effective on April 16, 2024.
Teladoc Health announced the appointment of Mala Murthy to the position of acting Chief Executive Officer of the Company, effective immediately.
replacing Jason Gorevic, who will also depart from the Board of Directors of the Company as required by his employment agreement.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.